Woodford Equity Income investors have missed out on a £550m lifeline as a specialist life sciences investor fails to secure enough money to buy a portfolio of illiquid companies from the suspended fund.
In November, WG Partners entered exclusive talks with PJT Partners, the investment bank responsible for winding up the illiquid part of the Woodford Equity Income fund, to buy 20 biotech companies from the portfolio.
But WG Partners missed its 31 January deadline to assemble enough investors to buy the portfolio, The Times reports.
Immunocore, Oxford Nanopore and Rutherford Cancer Centres, formerly Proton Partners, were reportedly among the portfolio WG Partners was looking to purchase.
WG Partners already lists a number of Woodford holdings among its clients, including Evgen, hVivo, E-therapeutics, Mereo Biopharma and Circassia.
Last week, German single family office Obotritia Capital purchased the fund’s 16.42% stake in Reneuron.
